OncoMatch/Clinical Trials/NCT07262619
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Is NCT07262619 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including EIK1005 and pembrolizumab (KEYTRUDA® ) for advanced solid tumors.
Treatment: EIK1005 · pembrolizumab (KEYTRUDA® ) — The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Gastric Cancer
Colorectal Cancer
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment regimen — advanced
has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting
Cannot have received: Werner (WRN) inhibitor
has received prior treatment with Werner (WRN) inhibitor
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Morristown Medical Center · Morristown, New Jersey
- Memorial Sloan Kettering Cancer Center (MSKCC) · New York, New York
- University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify